Flex Pharma has begun a Phase II clinical trial (COMMEND) of FLX-787 in the US to treat patients suffering from motor neuron disease (MND) with a focus on amyotrophic lateral sclerosis (ALS).
FLX-787 is a co-activator of TRPA1 and TRPV1, and ALS is characterised by painful and debilitating cramps.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The US Food and Drug Administration (FDA) has granted fast-track designation to FLX-787 for the treatment of severe muscle cramps associated with ALS.
Designed to assess 30mg of FLX-787 three times a day, the randomised, controlled, double-blinded, parallel design Phase II trial will be performed over a period of 28 days.
Flex Pharma president and CEO Dr William McVicar said: “The fast-track designation for FLX-787 is a validation by FDA that cramps are a severe, unmet medical need in ALS.
“While physicians treating ALS patients have come to understand how great an impact severe cramping – and the pain that attends it – can have on the lives of ALS patients, the lack of safe and effective and treatments has provided little impetus to focus on the problem.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe COMMEND trial will include a run-in period to determine a baseline in cramp frequency, and will measure cramp frequency changes as the primary endpoint, along with various secondary endpoints.
Top-line results from the trial are expected to be reported in the middle of next year, with plans to further study FLX-787 in a Phase II clinical trial for treating Charcot-Marie-Tooth (CMT) over the coming months.
